Review: No role for convalescent plasma in most COVID hospital patients

A prospective meta-analysis of international randomized clinical trials (RCTs) of convalescent plasma for the treatment of hospitalized COVID-19 patients finds no clinical benefit in most cases. Convalescent plasma, considered an experimental treatment by the US Food and Drug Administration (FDA), is donated by COVID-19 survivors in the hope that recipients with current infections benefit from the anti–SARS-CoV-2 antibodies. On Dec 28, 2021, the FDA restricted the use of convalescent plasma to patients with impaired immune systems.